The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age | Biomarker Research | Full Text

The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age | Biomarker Research | Full Text

The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age

• Yongfeng Wu, 
• Jinming Xu, 
• Jiawei Xu, 
• Yiqing Wang, 
• Luming Wang, 
• Wang Lv & 
• Jian Hu 

Biomarker Research volume 8, Article number: 9 (2020) Cite this article

• 3 Accesses
• Metricsdetails

Abstract

High tumor mutation burden (TMB), which is associated with increased tumor immunogenicity, has been identified to predict improved response to immune checkpoint inhibitors (ICIs) therapy in non-small cell lung cancer (NSCLC). As host immunity is also significant to eliminate cancer cells, however, its clinical impact on cancer immunotherapy is still largely unknown. Here we explored the influence of age, which is an important characteristic to evaluate immune response of patients, on TMB-based predictive system for ICIs therapy in NSCLC. Our results showed that high TMB was capable of predicting better durable clinical benefit (DCB) in agelow group, while it was insignificant in agehigh group. Besides, the predictive power of TMB for progression-free survival (PFS) and overall survival (OS) was better in agelow group than in agehigh group. Our study illustrated that the predictive value of TMB for ICIs therapy was better in young patients than in elderly patients in NSCLC.